晚期大肠癌患者化疗前后T淋巴细胞亚群检测的临床价值

萧剑军; 彭杰文; 贺景焕; 江小梅; 何洁冰

doi:10.3971/j.issn.1000-8578.2010.08.019

晚期大肠癌患者化疗前后T淋巴细胞亚群检测的临床价值

1. 528403广东中山，中山大学附属中山医院化疗科；2.中山市肿瘤研究所

详细信息

中图分类号: R735.3
计量
- 文章访问数: 2372
- HTML全文浏览量: 41
- PDF下载量: 330
出版历程
- 收稿日期: 2009-06-17
- 修回日期: 2010-02-22
- 刊出日期: 2010-08-24

Effects of Chemotherapy on T-lymphocyte Subgroups in Patients with Advanced Colorectal Cancer

1. Department of Oncology Chemotherapy,Zhongshan People's Hospital，Zhongshan 528403，China; 2. Zhongshan Cancer Research Institute

摘要

摘要: 目的：探讨晚期大肠癌患者T淋巴细胞亚群免疫功能状态及临床意义。方法：采用流式细胞术检测晚期大肠癌患者化疗前后外周血T淋巴细胞亚群的变化，并与体检健康者作比较。结果：实验组84例晚期大肠癌患者化疗前外周血T淋巴细胞亚群与35例正常对照组比较，CD4⁺、CD8⁺CD28⁺，CD28⁺明显低于对照组（P<0.01），CD8⁺CD28^-高于对照组（P<0.01），CD3⁺、CD8⁺、CD4⁺/CD8⁺比值与对照组比较差异无统计学意义（P>0.05）。对于69例接受化疗的患者，临床获益39例，化疗后CD3+较化疗前升高（P<0.05），CD8⁺、CD8⁺CD28^-较前明显降低（P<0.01），CD4⁺、CD8⁺CD28⁺、CD28⁺、CD4⁺/CD8⁺较前明显升高（P<0.01）；临床进展30例，化疗后CD8⁺、CD8⁺CD28^-较化疗前明显升高（P<0.01），CD4⁺、CD4⁺/CD8⁺较前明显降低（P<0.01），CD28+较前降低（P<0.05），CD3⁺、CD8⁺CD28⁺较前有所下降，但差异无统计学意义（P>0.05）。结论：晚期大肠癌患者免疫功能低下，有效的化疗能提高患者的T淋巴细胞免疫功能，临床上检测患者外周血T淋巴细胞亚群，特别是联合检测CD8⁺CD28⁺、CD8⁺CD28^-、CD28⁺T细胞对评估晚期大肠癌患者的细胞免疫功能及病情具有更积极的临床价值。
- 晚期大肠癌 /
- 流式细胞术 /
- T淋巴细胞亚群
Abstract: Objective：To explore T-lymphocyte subgroups immune function of advanced colorectal cancer patients and its clinical significance. Methods：The change of T-lymphocyte subgroups was measured with flow cytometry before and after treatment in the patients with advanced colorectal cancer compared with the healthy control group. Results：The 84 cases of advanced colorectal cancer in patients with T-lymphocyte subgroups compared with 35 cases of normal control group, CD4⁺,CD8⁺CD28⁺,CD28⁺ were significantly lower than the control group (P<0.01), CD8⁺CD28^- was higher than control group (P<0.01),CD3⁺,CD8⁺,CD4⁺/CD8⁺ ratio were no significant difference compared with the control group(P>0.05).The 69 cases were respected chemotherapy,clinical benefit of 39 cases,after chemotherapy,CD3+ were higher than that in pre-treatment (P<0.05), CD8⁺,CD8⁺CD28^- were significantly lower (P<0.01), CD4⁺,CD8⁺CD28⁺、CD28⁺,CD4⁺/CD8⁺ ratio were significantly higher (P<0.01); clinical ineffective of 30 cases, after chemotherapy, CD8⁺、CD8⁺CD28^- were significantly higher than that in pre-treatment (P<0.01), CD4⁺、CD4⁺/CD8⁺ ratio were significantly lower (P<0.01), CD28⁺ were lower (P<0.05), CD3⁺、CD8⁺ CD28⁺were lower,but no significant difference (P>0.05). Conclusion ：The immunity was suppressed in the patients with advanced colorectal cancer and immunity of the patients can be improved by effective chemotherapy.So clinical observation to the T-lymphocyte subgroups expression,in particular the joint detection CD8⁺CD28⁺、CD8⁺CD28^-、CD28⁺Tcells to assess advanced colorectal cancer cells in patients with immune function and disease is more positive clinical significance.
- Gastrointestinal cancer /
- Flow cytometry /
- T-lymphocyte subgroups